Scarica l'app Stockscreener
9.30
5.58%
-0.55
Dopo l'orario di chiusura:
9.20
-0.10
-1.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$9.85
Aprire:
$9.64
Volume 24 ore:
5.86M
Relative Volume:
1.37
Capitalizzazione di mercato:
$1.53B
Reddito:
$596.34M
Utile/perdita netta:
$-87.84M
Rapporto P/E:
-15.56
EPS:
-0.5975
Flusso di cassa netto:
$-97.62M
1 W Prestazione:
-10.06%
1M Prestazione:
+17.87%
6M Prestazione:
-13.00%
1 anno Prestazione:
+16.83%
Intervallo 1D:
$9.11
$9.68
Intervallo di 1 settimana:
$9.11
$10.75
Portata 52W:
$6.20
$11.97
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.30 | 1.62B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Iniziato | Citigroup | Sell |
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot - Yahoo Finance
Transcript : Novavax, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10 - marketscreener.com
Novavax at Citi summit: partnerships extend cash runway By Investing.com - Investing.com India
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference - Yahoo Finance
Novavax at cantor healthcare conference: pivot to licensing gains steam By Investing.com - Investing.com Canada
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
NVAX: Strategic shift to licensing and Matrix-M partnerships drives growth in vaccines and oncology - TradingView
NVAX: Major pharma partnerships, Matrix-M expansion, and global commercialization drive future growth - TradingView
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
NVAX Form 4 FilingsNovavax Inc SEC Form 4 - Stock Titan
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Trading the Move, Not the Narrative: (NVAX) Edition - Stock Traders Daily
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Inc. (NVAX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Novavax Inc (NVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Novavax to Participate in September Investor Conferences - Morningstar
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor - Benzinga
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story? - Yahoo Finance
What's Going On With Novavax Stock? - Benzinga
Novavax's Nuvaxovid Gets XFG-Variant Approval in US, EU, and Japan Ahead of 2026-2027 Season - BioPharm International
Novavax Stock Climbs Monday: What's Going On? - Benzinga
How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative - Yahoo Finance
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open - TradingView
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax -- Update - marketscreener.com
Gaithersburg's Novavax Sees Its Licensing Strategy Pay Off With XFG Vaccine Approvals Across Three Major Markets - biobuzz.io
Novavax partners receive approvals for updated COVID-19 vaccine By Investing.com - Investing.com Canada
Novavax's protein-based COVID vaccine gets approvals in the U.S., EU and Japan - Stock Titan
Novavax wins approvals for updated COVID shot (NVAX:NASDAQ) - Seeking Alpha
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax - Benzinga
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax Stock Rallies Tuesday: What's Happening? - TradingView
Novavax Inc. Stock Rallies 6.5%, Outperforms Peers - webull.com
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical - Yahoo Finance
NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough - Barchart.com
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):